Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy
Description
Syndromic optic atrophy, also known as DOA+ syndrome, is a neurologic disorder characterized most commonly by an insidious onset of visual loss and sensorineural hearing loss in childhood with variable presentation of other clinical manifestations including progressive external ophthalmoplegia (PEO), muscle cramps, hyperreflexia, and ataxia. There appears to be a wide range of intermediate phenotypes (Yu-Wai-Man et al., 2010).
Genes related to Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy
- OPA1
- ATP1A3
Clinical Features
Top most frequent phenotypes and symptoms related to Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy
- Seizures
- Hearing impairment
- Ataxia
- Strabismus
- Sensorineural hearing impairment
- Muscle weakness
- Spasticity
- Ptosis
- Cognitive impairment
- Anemia
And another 36 symptoms. If you need more information about this disease we can help you.
Incidence and onset information
— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)— No data available about the known clinical features onset.
Alternative names
Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy Is also known as dominant optic atrophy plus syndrome, doa+.
Researches and researchers
Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy Recommended genes panels
Panel Name, Specifity and genes Tested/covered |
---|
MitoMet®Plus aCGH Analysis.
By Baylor Miraca Genetics Laboratories (United States).
RGS9, RHO, GRK1, RLBP1, RNASEL, BCS1L, RP1, RP2, RP9, RPE65, RPGR, RPL35A, MRPL3, RPS14, RS1, SAG, SARDH, SCO2, SCP2, SDHB , (...)
View the complete list with 612 more genes
Specificity
1 %
Genes
50 % |
OPA1 Comprehensive - Sequence & Deletion/Duplication Analysis.
By Baylor Miraca Genetics Laboratories (United States).
OPA1
Specificity
100 %
Genes
50 % |
OPA1 Deletion/Duplication Analysis.
By Baylor Miraca Genetics Laboratories (United States).
OPA1
Specificity
100 %
Genes
50 % |
OPA1 Sequence Analysis (Prenatal Diagnosis).
By Baylor Miraca Genetics Laboratories (United States).
OPA1
Specificity
100 %
Genes
50 % |
mtDNA Depletion/Integrity Panel (MitomeNGS).
By Baylor Miraca Genetics Laboratories (United States).
SLC25A4, SUCLA2, SUCLG1, SUCLG2, TWNK, TK2, MGME1, RRM2B, DGUOK, TYMP, MPV17, OPA1, OPA3, POLG, POLG2
Specificity
7 %
Genes
50 % |
PEO Panel (MitomeNGS).
By Baylor Miraca Genetics Laboratories (United States).
SLC25A4, TWNK, MGME1, RRM2B, OPA1, OPA3, POLG, POLG2
Specificity
13 %
Genes
50 % |
OPA1 DNA Sequencing Test (Related to mtDNA depletion).
By Athena Diagnostics Inc (United States).
OPA1
Specificity
100 %
Genes
50 % |
Progressive External Ophthalmoplegia Evaluation (POLG, TWINKLE, ANT1, OPA1, MELAS).
By Athena Diagnostics Inc (United States).
SLC25A4, TWNK, MT-TL1, OPA1, POLG
Specificity
20 %
Genes
50 % |
You can get up to 159 more panels with our dedicated tool
Learn moreSources and references
You can check the following sources for additional information.
OMIM Genetic Syndrome FinderIf you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like OCULOCUTANEOUS ALBINISM TYPE 1A HYPERLYSINEMIA, TYPE I CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E NEPHROTIC SYNDROME, TYPE 1; NPHS1 LONG QT SYNDROME 15; LQT15 SPECIFIC LANGUAGE IMPAIRMENT 5; SLI5